Use of DAMPs and SAMPs as Therapeutic Targets or Therapeutics: A Note of Caution.
Biomarkers
/ blood
Cell-Free Nucleic Acids
/ blood
Chronic Disease
Coronavirus Infections
/ drug therapy
HMGB1 Protein
/ blood
Homeostasis
Humans
Immunity, Innate
/ drug effects
Inflammation
/ drug therapy
Molecular Targeted Therapy
/ methods
Pathogen-Associated Molecular Pattern Molecules
/ metabolism
S100 Proteins
/ blood
Vaccination
COVID-19 Drug Treatment
Journal
Molecular diagnosis & therapy
ISSN: 1179-2000
Titre abrégé: Mol Diagn Ther
Pays: New Zealand
ID NLM: 101264260
Informations de publication
Date de publication:
06 2020
06 2020
Historique:
pubmed:
6
4
2020
medline:
20
6
2020
entrez:
6
4
2020
Statut:
ppublish
Résumé
This opinion article discusses the increasing attention paid to the role of activating damage-associated molecular patterns (DAMPs) in initiation of inflammatory diseases and suppressing/inhibiting DAMPs (SAMPs) in resolution of inflammatory diseases and, consequently, to the future roles of these novel biomarkers as therapeutic targets and therapeutics. Since controlled production of DAMPs and SAMPs is needed to achieve full homeostatic restoration and repair from tissue injury, only their pathological, not their homeostatic, concentrations should be therapeutically tackled. Therefore, distinct caveats are proposed regarding choosing DAMPs and SAMPs for therapeutic purposes. For example, we discuss the need to a priori identify and define a context-dependent "homeostatic DAMP:SAMP ratio" in each case and a "homeostatic window" of DAMP and SAMP concentrations to guarantee a safe treatment modality to patients. Finally, a few clinical examples of how DAMPs and SAMPs might be used as therapeutic targets or therapeutics in the future are discussed, including inhibition of DAMPs in hyperinflammatory processes (e.g., systemic inflammatory response syndrome, as currently observed in Covid-19), administration of SAMPs in chronic inflammatory diseases, inhibition of SAMPs in hyperresolving processes (e.g., compensatory anti-inflammatory response syndrome), and administration/induction of DAMPs in vaccination procedures and anti-cancer therapy.
Identifiants
pubmed: 32248387
doi: 10.1007/s40291-020-00460-z
pii: 10.1007/s40291-020-00460-z
pmc: PMC7127836
doi:
Substances chimiques
Biomarkers
0
Cell-Free Nucleic Acids
0
HMGB1 Protein
0
HMGB1 protein, human
0
Pathogen-Associated Molecular Pattern Molecules
0
S100 Proteins
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
251-262Références
Front Pharmacol. 2019 Mar 07;10:169
pubmed: 30899221
Medicina (Kaunas). 2019 Jun 18;55(6):
pubmed: 31216723
Clin Chem. 1998 May;44(5):1056-8
pubmed: 9590385
Chem Res Toxicol. 2016 Dec 19;29(12):1956-1975
pubmed: 27629808
Haematologica. 2020 Aug;105(8):2056-2070
pubmed: 31780628
Front Immunol. 2018 Oct 16;9:2345
pubmed: 30459754
Cell Tissue Res. 2016 Sep;365(3):563-81
pubmed: 27324127
Science. 2002 Apr 26;296(5568):695-8
pubmed: 11976443
Metabolism. 2009 Dec;58(12):1688-93
pubmed: 19616266
FASEB J. 2020 Feb;34(2):2749-2764
pubmed: 31908042
Adv Exp Med Biol. 2019;1161:45-64
pubmed: 31562621
Int J Dev Biol. 2015;59(1-3):131-40
pubmed: 26374534
Oxid Med Cell Longev. 2019 Jun 18;2019:8107265
pubmed: 31316721
PLoS One. 2018 Jan 25;13(1):e0191676
pubmed: 29370247
Mol Cell Biochem. 2017 Oct;434(1-2):171-179
pubmed: 28474284
Oncogene. 2011 Sep 8;30(36):3887-99
pubmed: 21499310
Transplant Rev (Orlando). 2012 Apr;26(2):88-102
pubmed: 22000661
Nat Rev Immunol. 2012 Jun 22;12(7):479-91
pubmed: 22728526
Annu Rev Immunol. 1994;12:991-1045
pubmed: 8011301
Front Plant Sci. 2014 Oct 31;5:578
pubmed: 25400647
J Immunol. 2011 Nov 15;187(10):5408-18
pubmed: 22013115
Sci Rep. 2019 Oct 30;9(1):15660
pubmed: 31666644
Biophys Rev. 2018 Dec;10(6):1617-1629
pubmed: 30382555
Front Pharmacol. 2018 Sep 10;9:1015
pubmed: 30250432
Nat Rev Drug Discov. 2006 Oct;5(10):821-34
pubmed: 17016423
J Immunol. 2015 Mar 1;194(5):2330-7
pubmed: 25637017
Circ Res. 2016 Jun 24;119(1):91-112
pubmed: 27340270
Transplant Rev (Orlando). 2012 Apr;26(2):73-87
pubmed: 22074784
FASEB J. 2017 Apr;31(4):1273-1288
pubmed: 28087575
Cardiovasc Drugs Ther. 2020 Feb;34(1):123-131
pubmed: 32062794
Hepatology. 2016 Nov;64(5):1699-1710
pubmed: 27474782
Pharmacol Res. 2016 Sep;111:534-544
pubmed: 27378565
J Clin Invest. 2018 Aug 31;128(9):3727-3735
pubmed: 30168805
World J Gastroenterol. 2018 Nov 7;24(41):4622-4634
pubmed: 30416310
Eur J Trauma Emerg Surg. 2020 Aug;46(4):751-775
pubmed: 31612270
Sci Rep. 2013;3:1940
pubmed: 23736886
J Mol Cell Cardiol. 2014 May;70:74-82
pubmed: 24321195
Nat Commun. 2018 Aug 15;9(1):3261
pubmed: 30111884
J Neurosci. 2016 Sep 14;36(37):9590-603
pubmed: 27629711
Clin Exp Vaccine Res. 2015 Jan;4(1):23-45
pubmed: 25648619
Antioxid Redox Signal. 2016 Apr 20;24(12):620-34
pubmed: 26715031
Nat Med. 2011 Jul 17;17(8):996-1002
pubmed: 21765404
Environ Health Perspect. 2013 Apr;121(4):405-9
pubmed: 23380895
J Intern Med. 2019 Jul;286(1):2-15
pubmed: 30623510
Pharmacol Rev. 2006 Jun;58(2):259-79
pubmed: 16714488
Front Immunol. 2012 Nov 26;3:349
pubmed: 23189080
FASEB J. 2013 Jul;27(7):2573-83
pubmed: 23504711
J Chin Med Assoc. 2013 Sep;76(9):486-90
pubmed: 23769883
Environ Health Perspect. 2006 Jul;114(7):A398
pubmed: 16835037
EBioMedicine. 2019 Aug;46:264-273
pubmed: 31345784
J Cell Physiol. 2010 Nov;225(3):631-7
pubmed: 20635395
J Trauma Acute Care Surg. 2018 Aug;85(2):354-358
pubmed: 30080781
Drug Discov Today. 2012 Feb;17 Suppl:S24-30
pubmed: 22155646
Annu Rev Public Health. 2017 Mar 20;38:279-294
pubmed: 28068484
Radiat Oncol. 2019 May 10;14(1):78
pubmed: 31077235
Science. 2010 Oct 22;330(6003):460-1
pubmed: 20966241
Circ Res. 2012 Jan 6;110(1):159-73
pubmed: 22223212
Front Immunol. 2015 Nov 20;6:588
pubmed: 26635802
Sci Transl Med. 2016 Aug 24;8(353):353ra111
pubmed: 27559094
Curr Drug Targets. 2019;20(14):1474-1485
pubmed: 31215389
Expert Rev Clin Immunol. 2012 May;8(4):311-7
pubmed: 22607177
Crit Care Med. 2017 Jan;45(1):58-68
pubmed: 27632672
J Immunol. 2015 Feb 1;194(3):863-7
pubmed: 25539814
Am J Transplant. 2016 Dec;16(12):3322-3337
pubmed: 27529775
Coron Artery Dis. 2015 Jun;26(4):296-300
pubmed: 25714070
Expert Opin Ther Targets. 2016;20(2):223-39
pubmed: 26420647
Nat Rev Cardiol. 2010 Jan;7(1):30-7
pubmed: 19949426
Q J Nucl Med Mol Imaging. 2016 Sep;60(3):236-51
pubmed: 27225319
Mol Aspects Med. 2019 Feb;65:70-99
pubmed: 30056242
J Clin Invest. 2018 Jul 2;128(7):2657-2669
pubmed: 29757195
Front Cell Neurosci. 2019 Oct 15;13:466
pubmed: 31680874
Int Rev Cell Mol Biol. 2019;344:31-89
pubmed: 30798990
Sci Rep. 2019 Mar 26;9(1):5220
pubmed: 30914716
Front Biosci (Schol Ed). 2013 Jan 01;5:86-104
pubmed: 23277038
Microbiol Spectr. 2016 Jun;4(3):
pubmed: 27337457
FASEB J. 2014 Feb;28(2):836-48
pubmed: 24249635
Int Immunopharmacol. 2020 Mar;80:106134
pubmed: 31931365
Eur Rev Med Pharmacol Sci. 2015 Jun;19(12):2221-5
pubmed: 26166646
Blood. 2012 Oct 11;120(15):e60-72
pubmed: 22904297
Cancer Cell. 2018 May 14;33(5):862-873.e5
pubmed: 29706455
Int J Mol Sci. 2018 Apr 16;19(4):
pubmed: 29659553
Transplantation. 1994 Jan;57(2):211-7
pubmed: 8310510
Nat Commun. 2020 Jan 10;11(1):220
pubmed: 31924786
Expert Opin Ther Targets. 2018 Mar;22(3):263-277
pubmed: 29447008
Biofactors. 2013 Jul-Aug;39(4):355-67
pubmed: 23900966
Crit Care Clin. 2017 Jan;33(1):167-191
pubmed: 27894496
Front Pharmacol. 2019 Apr 02;10:252
pubmed: 31001110
Mol Aspects Med. 2017 Dec;58:12-20
pubmed: 28365269
Immunity. 2016 Mar 15;44(3):450-462
pubmed: 26982353
Hum Vaccin Immunother. 2015;11(2):477-88
pubmed: 25692535
Oncoimmunology. 2012 Aug 1;1(5):786-788
pubmed: 22934283
Nat Rev Genet. 2011 May;12(5):329-40
pubmed: 21499294
J Med Chem. 2018 Jun 28;61(12):5093-5107
pubmed: 29268019
Clin Sci (Lond). 2019 Nov 15;133(21):2121-2141
pubmed: 31693730
Front Immunol. 2018 Nov 20;9:2619
pubmed: 30515151